Last reviewed · How we verify
Comparator: Sulfonylurea
Comparator: Sulfonylurea is a Sulfonylurea Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved for Type 2 diabetes mellitus.
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Comparator: Sulfonylurea |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Sulfonylureas bind to and inhibit ATP-sensitive potassium channels on the surface of pancreatic beta cells, leading to cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances
- Headache
Key clinical trials
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- A Study of BGM0504 in Participants with Type 2 Diabetes (PHASE3)
- Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) (PHASE4)
- Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) (PHASE4)
- Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Sulfonylurea CI brief — competitive landscape report
- Comparator: Sulfonylurea updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Comparator: Sulfonylurea
What is Comparator: Sulfonylurea?
How does Comparator: Sulfonylurea work?
What is Comparator: Sulfonylurea used for?
Who makes Comparator: Sulfonylurea?
What drug class is Comparator: Sulfonylurea in?
What development phase is Comparator: Sulfonylurea in?
What are the side effects of Comparator: Sulfonylurea?
What does Comparator: Sulfonylurea target?
Related
- Drug class: All Sulfonylurea drugs
- Target: All drugs targeting ATP-sensitive potassium channel (KATP channel)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing